Alpha Teknova, Inc.
NASDAQ · TKNOAlpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers’ product development, including commercialization. We have substantial expertise in manufacturing customer-specified formulations and have demonstrated the ability to manufacture and deliver our products to customers quickly. Due to our expertise in raw materials sourcing, chemical formulation, and quality control, developed over more th
From the 10-K filed Mar 2, 2026
as of Oct 22, 2026 · today 7.36, 72% of the way from low to high
No dividends on record.
A company that pays none, or whose history has not arrived yet, shows nothing here.
Valuation
Results, trailing twelve months
Balance and cash
Shares and market
Financial statements
Loss before income taxes +35.9% −$26.83M → −$17.20M, year ended Dec 31, 2025
Comps
Valuation, growth and margins against the closest competitors
Filings
10-K filed Mar 2, 2026 · 10-Q Aug 6, 2026
| Filing | Filed |
|---|---|
| 10-Q for Quarter Ended June 2026 | Aug 6, 2026 |
| 10-Q for Quarter Ended March 2026 | May 7, 2026 |
| 10-K for Fiscal Year Ended December 2025 | Mar 2, 2026 |
| 10-Q for Quarter Ended September 2025 | Nov 7, 2025 |
Insiders
$40.51K sold $143.42K bought · open market, 12 months to Mar 6, 2026
| Insider | Type | Value |
|---|---|---|
| Stephen GunstreamMar 6, 2026 | Purchase | $55.80K ↗ |
| Matthew LowellMar 6, 2026 | Purchase | $87.62K ↗ |
| Martha J DemskiJun 27, 2025 | Sale | $40.51K ↗ |
Funds (13F)
17.0% held by 84 managers · as of Sep 30, 2026
| Manager | Value | Change |
|---|---|---|
| ROYCE & ASSOCIATES LP | $9.44M | +592.23K (+55.4%) |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.17M | +1.17M (+265.3%) |
| Roubaix Capital, LLC | $8.97M | −302.95K (−16.1%) |
| BlackRock, Inc. | $5.00M | +163.01K (+22.7%) |
| UBS Group AG | $3.59M | +306.80K (+94.4%) |
Congress
92 trades 91 sales · 1 purchases · 1 members, 12 months
| Member | Type | Amount |
|---|---|---|
| Richard BlumenthalAug 12, 2026 | Sale | $1K–$15K |
| Richard BlumenthalAug 12, 2026 | Sale | $1K–$15K |
| Richard BlumenthalAug 12, 2026 | Sale | $1K–$15K |
| Richard BlumenthalAug 12, 2026 | Sale | $1K–$15K |
Short interest
15.01% of float · 5.82 days to cover · Oct 15, 2026
Short position, last two years · 48% of its 2-year range
Source: FINRA
In the press
No headlines in the business press in the last 30 days.
Company data reported to the SEC on EDGAR (CIK 1850902).
Member research
Everything on TKNO, in full
Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.